Date：27 July (Thursday)
Time：14:00 – 15:30 (GMT+8)
Taiwania Capital Management Corporation
Michael Huang joined Taiwania Capital Management Corporation as Managing Partner of Life Science Investments in 2018.
Prior to joining Taiwania, Michael was the Co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the field of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed licensing deals with Sihuan Pharmaceutical and Sanofi Korea. Prior to NPV Asia, he had served as head of IR for TWi Pharmaceuticals, Inc., a specialty generics company in Taiwan, and had played a critical role during TWi's IPO process.
Before working in the industry, Michael had over 12 years of experience as venture capitalist, focusing on investments in life science startups in US, Taiwan and Japan. Michael currently serves on the board of Annji Pharma, Elixiron Biotherapeutics, Fractyl Health, Frequency Therapeutics (FREQ), Point Robotics, Regenacy Pharmaceuticals, Viracta Therapeutics (VIRX) and Windgap Medical.
His expertise is in investing and managing early to late stage biotech and medical device companies in the Greater China, Japan, European and North America regions. He has proven track record in investment return, project management, operation management, business planning and financial planning.